title: Does Barrett's esophagus regress after surgery (or proton pump inhibitors)?
abstract: Barrett's esophagus, the condition in which metaplastic columnar epithelium that predisposes to cancer development replaces the squamous epithelium that normally lines the distal esophagus, is a complication of gastroesophageal reflux disease (GERD). Metaplasia is a potentially reversible condition, and partial regression of Barrett's metaplasia has been documented with effective medical or surgical therapy for GERD. The important issue for patient management is not whether antireflux treatment causes Barrett's esophagus to regress, but rather whether antireflux therapy prevents cancer in Barrett's esophagus. Proton pump inhibitors (PPIs) would be expected to prevent this cancer because they heal reflux esophagitis, reduce exposure to a potential carcinogen (acid), and might prevent acid-induced proliferation and cancer-promoting cytokine secretion by esophageal epithelial cells. Furthermore, observational studies have shown that PPI use is associated with a decreased incidence of neoplasia in Barrett's esophagus. In theory, successful antireflux surgery, which eliminates the reflux of both acid and bile, should be better for cancer prevention than medical therapy, which only decreases the reflux of acid. However, high-quality studies show no significant difference in cancer incidence between medically and surgically treated patients with GERD and Barrett's esophagus. Furthermore, for individual patients with nondysplastic Barrett's metaplasia, the cancer risk is so small and the number needed to treat for cancer prevention with surgery so large, that it does not matter whether or not surgery provides a tiny margin of extra protection against cancer beyond that provided by medical therapy. The cost and risks of the operation overwhelm any small, additional cancer protective benefit. Antireflux surgery is very effective at controlling the endoscopic signs and symptoms of GERD, but the operation should not be recommended to patients solely with the rationale that it protects against cancer better than medical therapy.
authors.affiliation: Department of Medicine, VA North Texas Healthcare System, and the University of Texas Southwestern Medical Center at Dallas, Dallas, Tex., USA.
authors.forename: Stuart Jon
authors.initials: SJ
authors.lastname: Spechler
mesh_terms: D001471:Barrett Esophagus / Q000150:complications / Q000188:drug therapy* / Q000601:surgery*; D004938:Esophageal Neoplasms / Q000209:etiology / Q000517:prevention & control; D005744:Gastric Acid / Q000378:metabolism; D005764:Gastroesophageal Reflux / Q000150:complications; D006801:Humans; D054328:Proton Pump Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D012074:Remission Induction
chemical_list: D054328:Proton Pump Inhibitors